At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy, Safety, and Tolerability of Cenerimod in Subjects With Moderate to Severe Systemic Lupus Erythematosus (SLE)
In Brief
A Phase 2 clinical trial evaluating Cenerimod 0.5 mg, Cenerimod 1 mg, and 4 other interventions for Systemic Lupus Erythematosus. Completed, enrolled 427 participants across 148 sites in 24 countries.
Detailed Summary
The purpose of the study is to assess the efficacy and safety of 4 doses of cenerimod versus placebo in adult subjects with systemic lupus erythematosus (SLE).
Study Details
Timeline
Interventions
Cenerimod will be supplied as a film-coated tablets at the dose of 0.5 mg
Cenerimod will be supplied as a film-coated tablets at the dose of 1 mg
Cenerimod will be supplied as a film-coated tablets at the dose of 2 mg
Cenerimod will be supplied as a film-coated tablets at the dose of 4 mg
Matching placebo will be supplied as identical film-coated tablets formulated with the same excipients but without the active ingredient, cenerimod
Cenerimod will be supplied as a film-coated tablets at the dose of 2 mg